Back to resultsExpanded Access for CC-4047
Primary Purpose
Multiple Myeloma
Status
No longer available
Phase
Locations
United States
Study Type
Expanded Access
Intervention
CC-4047
Sponsored by
About this trial
This is an expanded access trial for Multiple Myeloma focused on measuring Expanded Access, Compassionate Use
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Sites / Locations
- Celgene
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03723096
Brief Title
Expanded Access for CC-4047
Official Title
Expanded Access for CC-4047
Study Type
Expanded Access
2. Study Status
Record Verification Date
December 2018
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Celgene
4. Oversight
5. Study Description
Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-4047.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Myeloma
Keywords
Expanded Access, Compassionate Use
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
CC-4047
Other Intervention Name(s)
Pomalyst, Pomalidomide
Intervention Description
CC-4047 will be administered orally
10. Eligibility
Sex
All
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Facility Information:
Facility Name
Celgene
City
Summit
State/Province
New Jersey
ZIP/Postal Code
07901
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Expanded Access for CC-4047
We'll reach out to this number within 24 hrs